Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-dependent kinase inhibitor 1B (CDKN1B)
- Target
- CDKN1B
- Molecular classification
- Enzyme, Cyclin-dependent kinase inhibitor, Cell cycle regulator, Other
01
Overview
Cyclin-dependent kinase inhibitor 1B (CDKN1B) encodes the protein p27Kip1, a critical negative regulator of cell cycle progression. It binds to cyclin-CDK2 and cyclin-CDK4 complexes, inhibiting their kinase activity and thereby enforcing cell cycle arrest at the G1 phase. As a tumor suppressor, loss or downregulation of p27 is frequently observed in a wide range of human cancers and is associated with poor prognosis. CDKN1B is also implicated in inherited tumor syndromes, notably multiple endocrine neoplasia type 4. Therapeutically, modulation of this pathway is a key mechanism for many anti-cancer agents, especially CDK inhibitors[1][2][3][6].
- Other names
- p27p27Kip1KIP1P27KIP1Cyclin-dependent kinase inhibitor p27MEN1BMEN4CDKN4
02
Mechanism of action
Inhibition of cyclin-CDK activity, Induction of G1 phase cell cycle arrest, Inhibition of cell proliferation via stabilization or upregulation of p27
03
Biological functions
Cell cycle regulationG1 phase arrestInhibition of cyclin/CDK complexesCell proliferation controlTumor suppression
04
Disease associations
CancerMultiple endocrine neoplasiaEndocrine tumorsPrimary hyperparathyroidismOther
05
Safety considerations
Myelosuppression (for drugs targeting this pathway)Off-target cell cycle inhibitionPossible adverse effects on normal proliferating cellsEndocrine disturbances with germline mutations
06
Interacting drugs
Palbociclib
4 more in the full profile.
07
Biomarkers
p27 expression (immunohistochemistry or mRNA) for prognosis in cancer (e.g., breast, prostate, and others)Decreased p27 as indicator of aggressive malignancy
Beyond the preview
Go deeper on Cyclin-dependent kinase inhibitor 1B (CDKN1B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin-dependent kinase inhibitor 1B (CDKN1B).